New treatment options for HER2-positive metastatic breast cancer with leptomeningeal metastases
Open Access
- 24 July 2024
- journal article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 46-53
Abstract
The molecular subtype of breast cancer associated with overexpression of HER2/neu is characterized by more frequent and earlier metastasis to the central nervous system, predetermining an unfavorable prognosis for patients in this category. Patients with secondary brain damage by tumors of any location and histological structure are the most complex group of patients, demonstrating an extremely low level of quality of life, requiring special close monitoring and the development of a personal management algorithm. The development of leptomeningeal lesions doubly complicates the specialist’s task due to the severity of the clinical course and resistance to any therapeutic interventions. The emergence in practice of a new drug a conjugate of the humanized antibody immunoglobulin G1 and the topoisomerase I inhibitor, the exatecan derivative trastuzumab deruxtecan (T-DXd) as an additional therapeutic option is new hope for patients with metastatic breast cancer (mBC), including those with damage to the central nervous system. This article provides an overview of the effectiveness and safety of T-DXd in registration studies, demonstrating the clinical benefit of therapy in a patient with HER2-positive (HER2+) mBC with meningeal involvement in real-world clinical practice.Keywords
This publication has 37 references indexed in Scilit:
- Leptomeningeal Metastases: New Opportunities in the Modern EraNeurotherapeutics, 2022
- 279P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)Annals of Oncology, 2021
- Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab DeruxtecanClinical Pharmacology & Therapeutics, 2021
- Primary Trastuzumab Resistance After (Neo)adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world PracticeClinical Breast Cancer, 2021
- Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE RegistryBreast Cancer Research and Treatment, 2021
- Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United StatesBreast Cancer Research and Treatment, 2016
- Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcomeBreast Cancer Research and Treatment, 2013
- Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtypeBreast Cancer Research and Treatment, 2012
- Disparities in breast cancer prognostic factors by race, insurance status, and educationCancer Causes & Control, 2010
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancerCancer, 2008